UCB (UCBJY) Days Payable : 317.29 (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is UCB Days Payable?

UCB's average Accounts Payable for the six months ended in Jun. 2024 was $1,593 Mil. UCB's Cost of Goods Sold for the six months ended in Jun. 2024 was $916 Mil. Hence, UCB's Days Payable for the six months ended in Jun. 2024 was 317.29.

The historical rank and industry rank for UCB's Days Payable or its related term are showing as below:

UCBJY' s Days Payable Range Over the Past 10 Years
Min: 75.76 Med: 107.97 Max: 346.85
Current: 346.85

During the past 13 years, UCB's highest Days Payable was 346.85. The lowest was 75.76. And the median was 107.97.

UCBJY's Days Payable is ranked better than
70.73% of 714 companies
in the Biotechnology industry
Industry Median: 127.37 vs UCBJY: 346.85

UCB's Days Payable increased from Jun. 2023 (297.44) to Jun. 2024 (317.29). It may suggest that UCB delayed paying its suppliers.

UCB Days Payable Historical Data

The historical data trend for UCB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Days Payable Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

111.64

117.97

145.74

131.70

116.92

UCB Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Days Payable	Get a 7-Day Free Trial															321.49	319.71	297.44	259.90	317.29

Competitive Comparison of UCB's Days Payable

For the Biotechnology subindustry, UCB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCB's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Days Payable distribution charts can be found below:

* The bar in red indicates where UCB's Days Payable falls into.

UCB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

UCB's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (606.992	+	585.605)	/	2 )	/	1861.505	*	365
=	596.2985					/	1861.505	*	365
=	116.92

UCB's Days Payable for the quarter that ended in Jun. 2024 is calculated as:

	Days Payable (Q: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
=	( (585.605	+	2599.569)	/	2 )	/	916.039	*	365 / 2
=	1592.587					/	916.039	*	365 / 2
=	317.29

UCB Days Payable Related Terms

Thank you for viewing the detailed overview of UCB's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJY) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).